AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06036784
Drug: MBX 1416 (Part B)
RxNorm normalized name: MBX-2109
DrugBank: MBX-2109 (DB18658)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated ascending subcutaneous (SC) doses of MBX 1416: 10mg, 30mg, 100mg
Trial: NCT06036784
Drug: MBX 1416 (Part C)
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single subcutaneous (SC) dose of MBX 1416 and the single dose of rosuvastatin and acetaminophen pharmacokinetics. The doses selected for MBX 1416 in Part C will not exceed a dose of 200mg.
Trial: NCT04305106
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (7.5mg/kg BW) + Saline (100ml) Bevacizumab will be administered in a single dose with no less than 90 minutes of intravenous infusion under ECG monitoring.
Trial: NCT06184139
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol for induction of labor in late term pregnancies
Trial: NCT04891497
Drug: Dimethyl Fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate 240mg orally twice daily for 3 consecutive days
Trial: NCT05228834
Drug: Voxelotor Only Product in Oral Dose Form
RxNorm normalized name: Voxelotor only product in oral dose form
DrugBank: Voxelotor (DB14975)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: During the Randomized Treatment Period, participants will be randomized in a 1:1 ratio to receive 1500 mg of voxelotor (or the weight-adjusted equivalent dose for participants \< 12 years old), once daily (administered orally as tablets/PFOS) or matching placebo for 12 weeks in addition to ongoing standard of care (SOC) treatment.
Trial: NCT05055934
Drug: SHR-1314 injection
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1314 injection
Trial: NCT05090904
Drug: Brensocatib
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05525234
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
Trial: NCT00375323
Drug: NovoSeven
RxNorm normalized name: NovoSeven
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04405180
Drug: 20mg sodium nitrite tid
RxNorm normalized name: Sodium Nitrite
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral, inorganic sodium nitrite capsule at a dose of 20 mg administered three times per day, during the day.
Trial: NCT05480865
Drug: BBP-398
RxNorm normalized name: BBP-812
DrugBank: BBP-812 (DB16983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BBP-398 administered orally
Trial: NCT05480865
Drug: sotorasib
RxNorm normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sotorasib administered orally
Trial: NCT06498323
Drug: tenecteplase
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous thrombolytic agents administration
Trial: NCT05526222
Drug: Jaktinib Hydrochloride Tablet
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered, twice a day
Trial: NCT06222437
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: effectiveness of semaglutide in PCOS
Trial: NCT05197504
Drug: atezolizumab plus bevacizumab
RxNorm normalized name: Atezolizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1200 mg of atezolizumab plus 15 mg/kg of body weight of bevacizumab intravenously every 3 weeks
Trial: NCT04660110
Drug: IPT with Dihydroartemisinin Piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose/round of IPT with Dihydroartemisinin Piperaquine (40mg/320mg tabs, Fosun Pharmaceuticals)
Trial: NCT05467670
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A type of immunotherapy that stimulates the body's immune system to fight cancer cells by targeting and blocking PD-1 proteins on the surface of certain immune T-cells, thus triggering the T-cells to find and kill cancer cells.
Trial: NCT05467670
Drug: ALX148
RxNorm normalized name: Sirpa variant alx148
DrugBank: Evorpacept (DB17573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fusion protein comprised of a high affinity CD47 blocker linked to an inactive immunoglobulin Fc region, enhancing innate and adaptive immune responses against cancer.
Trial: NCT05114499
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 5mg qd
Trial: NCT05988710
Drug: Buccal Buprenorphine 300 mcg
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine for 300mcg buccal administration
Trial: NCT05988710
Drug: Buccal Buprenorphine 600 mcg
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine for 600mcg buccal administration
Trial: NCT05988710
Drug: Buccal Buprenorphine 900 mcg
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine for 900mcg buccal administration. Note: This arm has been discontinued as of 06/25/2024 and has been replaced with the 450mcg buprenorphine buccal administration arm.
Trial: NCT05988710
Drug: Oral immediate-release oxycodone 10mg
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate-release oxycodone for 10 mg oral administration
Trial: NCT05988710
Drug: Buccal Buprenorphine 450mcg
RxNorm normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: buprenorphine for 450mcg buccal administration. Note: This arm has been added to replace the 900mcg buprenorphine buccal administration arm.
Trial: NCT05245734
Drug: Human Anti-D (rh) immunoglobulin
RxNorm normalized name: Human anti-D (rh) immunoglobulin
DrugBank: Human Rho(D) immune globulin (DB11597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prevention of Rh-sensitization in pregnant women in the antenatal and postnatal period in routine clinical practice. The study drug is administered twice at a dose of 300 mcg - at 28 weeks of gestation and within 72 hours after delivery.
Trial: NCT06671938
Drug: exidavnemab
RxNorm normalized name: Exidavnemab
DrugBank: Exidavnemab (DB19452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The trial medication will be administered as an intravenous (IV) infusion (dose 1; dose 2)
Trial: NCT05792995
Drug: Sindillimab
RxNorm normalized name: Sintilimab
DrugBank: Dill (DB10673)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any treatment regimen that includes immunotherapy.
Trial: NCT06040034
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine given as bolus or continuous infusion.
Trial: NCT04436965
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in both arms received concurrent cisplatin chemotherapy:100 mg/m² cisplatin given intravenously every 3 weeks on days 1, 22 concurrently with radiotherapy.
Trial: NCT04643418
Drug: MPB-1734
RxNorm normalized name: MPB-1523
DrugBank: MPB-1523 (DB18334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once daily in a 21-day cycle
Trial: NCT05547061
Drug: Lu-177-DGUL
RxNorm normalized name: Lu 177
DrugBank: Lutetium Lu-177 (DB13982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.
Trial: NCT05547061
Drug: Ga-68-NGUL
RxNorm normalized name: Ga 68 DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously during screening and every 12 weeks after the first administration of Lu-177-DGUL.
Trial: NCT05207904
Drug: Tislelizumab, paclitaxel, Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tislelizumab, 200mg administered intravenously (IV) on Day 1 of each 21-day cycle paclitaxel 175 mg/m2 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6cycle Carboplatin AUC 5 administered intravenously (IV) on Day 1 of each 21-day cycle, 4-6 cycle
Trial: NCT05786768
Drug: single infusion of Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single infusion of Rituximab 375 mg/m2
Trial: NCT05786768
Drug: single infusion of Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single infusion of Obinutuzumab 300mg/1.73 m2
Trial: NCT05567029
Drug: Risankizumab Dose A
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prefilled Syringe
Trial: NCT05567029
Drug: Risankizumab Dose B
RxNorm normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prefilled Syringe
Trial: NCT05861102
Drug: Jaktinib
RxNorm normalized name: Jaktinib
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 100 mg Jaktinib orally twice daily for 16 weeks
Trial: NCT05490134
Drug: Naloxone
RxNorm normalized name: Naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 0.15 mg/kg bolus dose of naloxone in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
Trial: NCT05490134
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15mg/kg bolus of normal saline in 10ml normal saline will be administered via an intravenous (IV) line inserted into the antecubital vein of the non-dominant arm.
Trial: NCT05921149
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05921149
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05940896
Drug: Disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disitamab Vedotin intravenously combined with radiotherapy (concurrent)
Trial: NCT04982172
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (Inflectra® \[Pfizer\]), dosage determined using model-informed precision dosing, intravenously administered
Trial: NCT04982172
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab, dosage following a dose de-escalation algorithm at the physician's discretion, intravenously administered
Trial: NCT06404840
Drug: nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimotuzumab (400 mg, iv, d1, qw)
Trial: NCT06404840
Drug: AG chemotherapy
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (gemcitabine 1000mg/m², Nab-paclitaxel 125mg/m², d1, d8, 21d cycle)
Trial: NCT04902729
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Trial: NCT04902729
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
Trial: NCT04618211
Drug: Deucrictibant
RxNorm normalized name: Deucrictibant
DrugBank: Deucrictibant (DB18303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deucrictibant soft capsules for oral use
Trial: NCT06330220
Drug: Aflibercept Injection [Eylea]
RxNorm normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: intravitreal injection
Trial: NCT06625814
Drug: Enlicitide Decanoate
RxNorm normalized name: decanoic acid
DrugBank: Capric acid (DB03600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT06034977
Drug: ADI-PEG20
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lenvatinib + ADI-PEG20 combination treatment.
Trial: NCT05580328
Drug: Hematoporphyrin Injection actived by photodynamic therapy combined with Sonodynamic Therapy
RxNorm normalized name: hematoporphyrin
DrugBank: Hemoporfin (DB16183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hematoporphyrin in tumor tissue will be greatly enhanced by the combination of Sonodynamic Therapy and Photodynamic Therapy and achieve better treatment effect.
Trial: NCT06368882
Drug: Peg-Interferon α
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
Trial: NCT05406505
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: patients will receive once daily dapagliflozin 10 mg orally in addition to standard care
Trial: NCT05550441
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The experimental group received dapagliflozin (10 mg qd) for 1 year.
Trial: NCT06333405
Drug: Fecal Microbiota Transplantation
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedure: Fecal Microbiota Transplantation~Fecal Microbiota as a suspension obtained from healthy unrelated donor (woman in 3rd trimester of pregnancy) introduced two times per treatment:~* as a deep rectal infusion, via Foley's catheter inserted under ultrasound control, twice 6 hours apart, between 3 and 6 days after birth and/or up to 14 days~* Other Names: MBiotix HBI
Trial: NCT06178783
Drug: Brensocatib
RxNorm normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brensocatib oral solutions will be expectorated following the tasting.
Trial: NCT05756569
Drug: Enfortumab Vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06073470
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients with ADHD will receive 12-week treatment with methylphenidate.
Trial: NCT04624906
Drug: Acalabrutinib
RxNorm normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg oral capsules twice daily for 1 year
Trial: NCT04624906
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90 mg/m2 on days 1 and 2 of each cycle.
Trial: NCT04624906
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: day 1 of each cycle (375 mg/m2 intravenously for the first cycle and 1400 mg subcutaneously OR 375 mg/m2 intravenously for subsequent cycles (as per institutional procedures).
Trial: NCT05606796
Drug: Latanoprost 0.005% Ophthalmic Solution
RxNorm normalized name: Latanoprost 0.005% Ophthalmic Solution
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop of 0.005% Latanoprost (preserved or preservative-free) would be instilled into the conjunctival sac daily for 12 weeks.
Trial: NCT00001047
Drug: Ethambutol hydrochloride
RxNorm normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001047
Drug: Clofazimine
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001047
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05636150
Drug: Fruquintinib in Combination with S-1
RxNorm normalized name: fruquintinib 1 MG
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort A: Fruquintinib 3 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort B: Fruquintinib 4 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Cohort C: Fruquintinib 5 mg QD, oral dosing, 2 weeks on/1 weeks off+ S-1 40-60mg/time bid po d1-14 q3w.~Patients will be treated until disease progression, death, unacceptable toxicity, loss of follow-up, withdrawal of consent or other conditions meet the end of treatment criteria.
Trial: NCT05538091
Drug: Vismodegib
RxNorm normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A small-molecule SMO inhibitor designed to specifically target the hedgehog pathway, a known driver of BCC. It systemically inhibits hedgehog pathway signaling. Following mutation, SMO is released from the inhibitory effect of PTCH and moves to the cell surface, activating GLI. GLI travels to the nucleus and initiates transcription of target genes that regulate basal cell growth and proliferation.
Trial: NCT05538091
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is a humanized monoclonal antibody immune checkpoint inhibitor that selectively binds to PD-L1 to stop the interaction between PD-1 and B7.1 (CD80 receptors). The antibody still allows interaction between PD-L2 and PD-1.
Trial: NCT06255379
Drug: Fuquinitinib+Tegafur Gimeracil Oteracil
RxNorm normalized name: tegafur
DrugBank: Oteracil (DB03209)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Fuquinitinib:5 mg once daily, 2 weeks on/1 week off,q3w; Tegafur Gimeracil Oteracil:BSA(body surface area)\< 1.2m2,40mg/m2,p.o,bid,2 weeks on/1 week off,q3w; 1.2m2 \< BSA （body surface area）\< 1.5m2,50mg/m2,p.o,bid,2 weeks on/1 week off,q3w;BSA（body surface area） \>1.5m2,60mg/m2,p.o,bid,2 weeks on/1 week off,q3w;
Trial: NCT05706038
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab is a fully human, high-affinity, recombinant anti-tumor necrosis factor (TNF) alpha monoclonal antibody used to treat rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, ulcerative colitis, etc.~Adalimumab is a fully human, high-affinity, recombinant immunoglobulin G (IgG) anti-TNF alpha monoclonal antibody. It is a molecule comprising 1330 amino acids and has a molecular weight of approximately 148 kDa.\[4\] It inhibits the binding of TNF alpha (both soluble and membrane-bound) to its receptor. Specifically, it inhibits TNF alpha's interaction with p55 (TNFR1) and p75 (TNFR2) cell surface TNF receptors, which in turn interferes with cytokine-driven inflammatory processes. It is identical in structure and function to the naturally occurring human IgG1 and thus has high selectivity for TNF alpha and has low immunogenic potential.
Trial: NCT06507904
Drug: Osivelotor
RxNorm normalized name: Osivelotor
DrugBank: Osivelotor (DB18071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A medicine to treat sickle cell disease.
Trial: NCT05138159
Drug: Donafenib
RxNorm normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donafenib: 200mg po bid.
Trial: NCT05138159
Drug: S1
RxNorm normalized name: LS11
DrugBank: LS11 (DB05918)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, \> 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
Trial: NCT06537011
Drug: AK112
RxNorm normalized name: IMMUNOGLOBULIN G1 (240-ALANINE,241-ALANINE), ANTI-(HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A) (HUMAN-MUS MUSCULUS MONOCLONAL AK112 .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN PROGRAMMED CELL
DrugBank: Ivonescimab (DB18931)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. The patients are given AK112 combined with AP regimen every 3 weeks for 3 cycles before operation.~2. After the neoadjuvant therapy ,the patients will be assessed and be commanded surgery.~3.4-6 weeks after the surgery, the patients will be given chemoradiotherapy or radiotherapy alone decided on the conditon after surgery.~4.The participants will receive AK112 for 14 cycles after surgery.